?DESCRIPTION (provided by applicant): Human immunodeficiency virus-1 (HIV) infection accelerates cellular and organismal aging and substantially increases the risk of atherosclerosis. Endothelial progenitor cells (EPC) are actively involved in vascular homeostasis and arterial repair and can predict cardiovascular events. Senescent EPC have impaired repair capacity, which is associated with atherosclerosis development. The impact of HIV infection on EPC and the underlying mechanisms remain to be elucidated. MicroRNAs (miRNA) regulate the senescence of somatic stem cells. We have identified miR-10A*, miR-21, miR-146a, miR-29c and miR-126, as well as, their target genes, to be differentially expressed in young and old EPC/lineage negative bone marrow cells (lin- BMC) using genomic screening. Furthermore, we have demonstrated that these miRNA/target genes segregate into three miRNA signaling axes that control different basic processes of EPC/lin- BMC. Specifically, miR- 10A*/miR-21 ??hmga2 ??p16Ink4a/p19Arf mainly regulates cell self-renewal; miR-146a ??Plk2 pathway chiefly controls cell apoptosis; and miR-29c ??klf2a ??miR-126 ??spred-1 ??VEGF signaling predominantly governs differentiation, respectively. In addition, we have shown that modifying these three pathways can dramatically impact the senescence and the angiogenic and vascular repair capacity of EPC. The primary objective of the current proposal is to understand the impact of HIV infection on the circulating levels and functionality of EPC and the underlying mechanisms. Our central hypotheses are that HIV infection is associated with EPC senescence, which contributes to accelerated atherogenesis, and that the specific miRNA regulatory networks mediate this process. We will test these proof-of-principle hypotheses by examining the EPC levels in well- characterized clinical samples using multiple standardized approaches/techniques and testing their functionality using established cell culture procedures. We will further determine the role of candidate miRNA regulatory networks in mediating the effects of HIV on EPC functions. Results from these studies will offer understanding of EPC changes and the underlying molecular mechanisms in the pathogenesis of HIV- associated accelerated atherosclerosis, and may open an avenue for facilitating the design of novel therapeutic strategies for HIV-associated cardiovascular disease.
|Effective start/end date||5/1/15 → 4/30/18|
- National Institutes of Health: $230,250.00
- National Institutes of Health: $191,875.00